SALT Score Distribution With Ritlecitinib Treatment Up to 24 Months in Alopecia Areata

The study evaluated the long-term efficacy of ritlecitinib, a JAK3/TEC family kinase inhibitor, in treating alopecia areata (AA) over 24 months. It included 191 participants aged ≥12 years with ≥50% scalp hair loss. Results showed a reduction in participants with high Severity of Alopecia Tool (SALT) scores, with more participants moving to lower SALT score categories (0–10 and >10–20) by Month 24. This suggests ritlecitinib's effectiveness in improving hair regrowth over time. The study supports the use of ritlecitinib beyond 12 months, although results may be biased as they only include participants with available SALT scores.